Please use this identifier to cite or link to this item:
http://acervodigital.unesp.br/handle/11449/64750
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Agapejev, Svetlana | - |
dc.contributor.author | Da Silva, Maria Dorvalina | - |
dc.contributor.author | Ueda, Anete K. | - |
dc.date.accessioned | 2014-05-27T11:18:04Z | - |
dc.date.accessioned | 2016-10-25T18:13:48Z | - |
dc.date.available | 2014-05-27T11:18:04Z | - |
dc.date.available | 2016-10-25T18:13:48Z | - |
dc.date.issued | 1996-03-01 | - |
dc.identifier | http://dx.doi.org/10.1590/S0004-282X1996000100014 | - |
dc.identifier.citation | Arquivos de Neuro-Psiquiatria, v. 54, n. 1, p. 82-93, 1996. | - |
dc.identifier.issn | 0004-282X | - |
dc.identifier.uri | http://hdl.handle.net/11449/64750 | - |
dc.identifier.uri | http://acervodigital.unesp.br/handle/11449/64750 | - |
dc.description.abstract | Study of 22 patients with the severe form of neurocysticercosis treated with albendazole (ABZ) administered in 6 different schedules ranging from 15 to 30 mg/kg/day for 21 to 60 days. Dextrochloropheniramine and ketoprofen were the adjuvant drugs Multiple symptoms were observed in 90 9% of patients. Intracranial hypertension was manifested in 90.9%. Hydrocephaly occurred in 86.4%. Evolution was satisfactory in 10 patients, 8 died and 4 had sequelae. Tomographic studies showed the appearance of an isolated IVth ventricle in 9 patients, after ventriculoperitoneal shunt, before ABZ treatment in 3 of them, during in 5 and after treatment in one. Median clinical follow-up duration was 10 months for the patients who died and 3-4 years for survivors. In 3 patients there was an increase in cyst size during the administration of the 15 mg/kg/day ABZ dose, which was not observed in any patient when the 30 mg/kg/day dose was used. | en |
dc.format.extent | 82-93 | - |
dc.language.iso | eng | - |
dc.source | Scopus | - |
dc.subject | Albendazole | - |
dc.subject | Cysticercosis | - |
dc.subject | Dextrochloropheniramine | - |
dc.subject | Ketoprofen | - |
dc.subject | Neurocysticercosis | - |
dc.subject | Severe forms | - |
dc.subject | Treatment | - |
dc.subject | acetazolamide | - |
dc.subject | albendazole | - |
dc.subject | dexchlorpheniramine | - |
dc.subject | ketoprofen | - |
dc.subject | mannitol | - |
dc.subject | adolescent | - |
dc.subject | adult | - |
dc.subject | clinical article | - |
dc.subject | drug efficacy | - |
dc.subject | female | - |
dc.subject | human | - |
dc.subject | male | - |
dc.subject | neurocysticercosis | - |
dc.subject | Adolescent | - |
dc.subject | Adult | - |
dc.subject | Anthelmintics | - |
dc.subject | Brain Diseases | - |
dc.subject | Chlorpheniramine | - |
dc.subject | Female | - |
dc.subject | Follow-Up Studies | - |
dc.subject | Humans | - |
dc.subject | Male | - |
dc.subject | Middle Aged | - |
dc.subject | Prognosis | - |
dc.subject | Tomography, X-Ray Computed | - |
dc.title | Severe forms of neurocysticercosis: Treatment with albeimdazole | en |
dc.type | outro | - |
dc.contributor.institution | Universidade de São Paulo (USP) | - |
dc.contributor.institution | Universidade Estadual Paulista (UNESP) | - |
dc.description.affiliation | Division of Neurology Botucatu School of Medicine State University of São Paulo | - |
dc.description.affiliation | Dept. of Neurology and Psychiatry School of Medicine UNESP, P.O Box 540, 18618-000 Botucatu SP | - |
dc.description.affiliationUnesp | Dept. of Neurology and Psychiatry School of Medicine UNESP, P.O Box 540, 18618-000 Botucatu SP | - |
dc.identifier.doi | 10.1590/S0004-282X1996000100014 | - |
dc.identifier.scielo | S0004-282X1996000100014 | - |
dc.identifier.wos | WOS:A1996TZ93500014 | - |
dc.rights.accessRights | Acesso aberto | - |
dc.identifier.file | 2-s2.0-0029965675.pdf | - |
dc.relation.ispartof | Arquivos de Neuro-Psiquiatria | - |
dc.identifier.scopus | 2-s2.0-0029965675 | - |
Appears in Collections: | Artigos, TCCs, Teses e Dissertações da Unesp |
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.